White, P D, Cleary, K J · International clinical psychopharmacology · 1997 · DOI
This study tested whether a medication called moclobemide could help people with ME/CFS. Researchers gave 49 patients the drug for 6 weeks and found small improvements in fatigue, depression, and anxiety. The medication worked better for patients who also had depression, with half of them feeling much better, compared to only about one-fifth of those without depression.
Depression commonly co-occurs with ME/CFS and often goes untreated due to uncertainty about antidepressant efficacy in this population. This study provides early evidence that patients with both conditions may benefit from moclobemide, potentially offering clinicians a treatment option for a vulnerable subgroup of ME/CFS patients.
This open-label design without placebo control cannot distinguish drug effects from placebo response, which is particularly important for subjective outcomes like fatigue and mood. The small sample size and lack of a comparator group limit generalizability. The study does not establish whether moclobemide is effective for treating ME/CFS itself in patients without depression.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →